Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Equillium Inc
EQ | US
1.12
USD-0.01
-0.88%
EQ | US
About Equillium Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.12
Open
1.14
High
1.15
Low
1.03
Equillium Inc. a clinical-stage biotechnology company develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001) a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6 which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium Inc. was formerly known as Attenuate Biopharmaceuticals Inc. and changed its name to Equillium Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla California.
View LessEQ | US
Risk
108.1
Sharpe
0.45
Luna's Score
51/100
Recommendation
Hold
Luna says (EQ | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
138.9%1 month
108.1%3 months
95.3%6 months
99.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.53
Price to book
1.71
Debt to equity
0.03
Debt to assets
0.01
Ent. to EBITDA
0.07
Ent. to rev.
0.13
PEG
-
Other Fundamentals
EBITDA
-9.58M
MarketCap
39.68M
MarketCap(USD)
39.68M
Div. yield
-
Op. margin
-0.72
Erngs. growth
-
Rev. growth
51.80
Ret. on equity
-33.67
Short ratio
1.81
Short perc.
0.87
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.35
Range1M
0.42
Range3M
0.71
Volumes: Market Activity
Rel. volume
1.18
Price X volume
148.10K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.07 | 0.53 | Cheaper |
| Ent. to Revenue | 0.13 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.71 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 95.30 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 39.68M | 3.66B | Emerging |
